Lupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA
Lupin Ltd. has received an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium.
Published: June 21, 2026
Updated: June 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Antihypertensive
Company: Lupin Ltd.
Asset: Losartan Potassium
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Lupin Ltd.
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Lupin's receipt of AP status for Losartan Potassium is significant as it positions the company to compete more effectively in the cardiovascular market. This could disrupt pricing strategies and market share for existing players in the antihypertensive segment.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the launch timeline and market uptake of Lupin's Losartan Potassium product.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.